Hepatic Veno-occlusive disease (VOD) in multiple myeloma patient receiving Belantamab Mafodotin

Leuk Lymphoma. 2023 Apr;64(4):904-906. doi: 10.1080/10428194.2023.2179362. Epub 2023 Feb 15.

Authors

Ilias Pessach¹, Georgia Argyrakopoulou², Fotios Petropoulos³, Irene Rapti⁴, Fotios Danglis⁵, Enkeleida Trajce¹, Eleni Chandrinou¹

Affiliations

¹ Hematology Department, Athens Medical Center, Athens, Greece.
² Diabetes and Obesity Unit, Athens Medical Center, Athens, Greece.
³ Internal Medicine Clinic, Athens Medical Center, Athens, Greece.
⁴ Liver Unit, Athens Medical Center, Athens, Greece.
⁵ Pathology Department, Athens Medical Center, Athens, Greece.

PMID: 36794387
DOI: 10.1080/10428194.2023.2179362

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized
Hematopoietic Stem Cell Transplantation*
Hepatic Veno-Occlusive Disease* / diagnosis
Hepatic Veno-Occlusive Disease* / drug therapy
Hepatic Veno-Occlusive Disease* / etiology
Humans
Multiple Myeloma* / complications
Multiple Myeloma* / diagnosis
Multiple Myeloma* / drug therapy

Substances

belantamab mafodotin
Antibodies, Monoclonal, Humanized